NETRF 2019 RESEARCH SYMPOSIUM PROGRAM

DRAFT AGENDA

May 2-3, 2019
Norton's Woods Conference Center
American Academy of Arts & Sciences
135 Irving Street, Cambridge, MA

Thursday, May 2, 2019
DAY 1

Registration and Breakfast 8:00 – 8:30 am
Introductions and Welcome 8:30 – 8:40 am

Session I: Laboratory Models of NETS 8:40 – 10:20 am

Talya Dayton, PhD, Hubrecht Institute, Netherlands
Topic: Modeling neuroendocrine neoplasias using adult stem cell-derived organoids

Raj Srirajaskanthan, PhD, Kings College London, United Kingdom
Topic: Development of ex-vivo models of metastatic neuroendocrine tumors

Charlotte Kuperwasser, PhD, Tufts School of Medicine, Whitehead Institute, Massachusetts Institute of Technology, Cambridge, MA
Topic: Development of 3D models for neuroendocrine tumors

Pawel Mazur, PhD, University of Texas M.D. Anderson Cancer Center
Topic: Next generation animal models to define therapies for neuroendocrine tumors

Jesse Boehm, PhD, Broad Institute, Cambridge, MA
Topic: The NETRF/BROAD Cancer Cell Line Factory initiative

Q and A Discussion

Coffee Break 10:20 – 11:00 am

Session II: Immuno-oncology and NETS 11:00 – 11:55 am

Xianxin Hua, MD, PhD, University of Pennsylvania, Philadelphia, PA
Topic: Multipronged approaches to develop immunotherapy targeting NETs
Chrissie Thirlwell, MD, PhD, University College London, United Kingdom
Topic: Systematic evaluation of the immune environment of NETs

Renata Jaskula-Sztul, PhD, The University of Alabama at Birmingham
Topic: Novel antibody-drug conjugate (ADC) for PanNET targeted therapy

Q and A Discussion

Lunch 12:00 – 1:30 pm

Session III: Detecting and Targeting NETs 1:30 – 2:25 pm

Babak Behnam Azad, PhD, Johns Hopkins School of Medicine, Baltimore, MD, ERF 2018
Topic: A modified PET tracer for NET detection

Brian Untch, MD, Memorial Sloan Kettering Cancer Center, NY, NY, NANETS 2018
Topic: Somatostatin receptor ligands can be used to image and treat murine panNETs induced by MEN1-loss

Martin Gotthardt, MD, Radboud University Nijmegen Medical Centre, Netherlands
Topic: NETcure - shine new light on neuroendocrine tumor therapy

Q and A Discussion

Coffee Break 2:30– 3:00 pm

Session IV: Advances in NET Treatment: Nuclear Medicine 3:00 – 4:25 pm

Rodney Hicks, MD, University of Melbourne, Australia
Topic: Developing novel combination therapies for use with 177Lu-octreotate PRRT in NETs, focusing on DNA-repair mechanisms

Cristina Muller, Paul Scherrer, PhD, Institut, Switzerland
Topic: Simultaneous Auger e- and β-particle therapy of metastasized NET using 161Tb-DOTATOC

Thomas Hope, MD, University of California, San Francisco, CA, ERF 2017
Topic: Yttrium-90 DOTA-TOC intra-arterial PRRT for NET

David Morse, PhD, Moffitt Cancer Center, Tampa, FL
Topic: Evaluation of 225Ac-DOTATATE for treatment of lung carcinoid tumors

Kuo-Shyan Lin, PhD, BC Cancer, Vancouver, Canada,
**Topic:** Novel radioligands to improve radiotherapy of NETs

**Q and A discussion and wrap-up of day by chairs**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 – 5:30 pm</td>
<td>Reception</td>
</tr>
<tr>
<td>5:30 pm</td>
<td>End of Day 1</td>
</tr>
</tbody>
</table>

---

**Friday, May 3, 2019**

**DAY 2**

**Session I: Pre-clinical advances in NETs** 8:30 – 9:50 am

**Amanda Wasylishen, PhD**, (Gigi Lozano Lab), MD Anderson Cancer Center, Houston, TX  
**Topic:** Loss of DAXX and ATRX in development, tissue homeostasis, and pancreatic neuroendocrine tumorigenesis

**Joe Zhou, PhD**, Weill Cornell Medicine, NY, NY  
**Topic:** Epigenetic regulators of intestinal neuroendocrine cells and carcinoid tumors

**Chester Chamberlain, PhD**, (Michael German Lab), University of California, San Francisco, CA  
**Topic:** Pathways to Synthetic Lethal Combinations and New Drug Therapies for PNETs

**Q and A discussion**

**Coffee Break** 9:50 – 10:20 am

---

**Session II: Cracking the code** 10:20 – 12:10 pm

**Keynote:** William Sellers, MD, Broad Institute

**Matthew Meyerson, MD, PhD**, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA / Eric Nakakura, MD, PhD, UCSF / Chrissie Thirlwell, MD, PhD, UCL London  
**Topic:** Transcriptomic, genomic and epigenomic analysis of small intestinal NETs

**Laura Banaszynski, PhD**, UT Southwestern Medical Center, Dallas, TX  
**Topic:** The role of ATRX/DAXX/H3.3 chromatin regulation in PNETs

**Sharon Gorski, PhD**, Genome Sciences Centre, Canada  
**Topic:** Molecular characterization of primary and metastatic PanNETs

**Sita Kugel, PhD**, Fred Hutchinson Cancer Research Center, Seattle, Washington
Topic: Exploring the role of epigenetic dysregulation in PanNET progression

Q and A Discussion

Lunch 12:10 – 1:15 pm

Session III: New Clinical Strategies 1:15 – 3:00 pm

Jennifer Chan, MD, MPH, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Topic: Biomarkers of response to cabozantinib in patients with NETs

Emily Bergsland, MD, University of California San Francisco, CA
Topic: New strategies to improve drug development specific to carcinoid tumors

Renuka Iyer, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Topic: Phase 1 study of SurvaxM™ in surviving-positive NETs

Justin Annes, MD, PhD, Stanford University Medical Center, CA
Topic: NET-Smart chemotherapy: a targeted prodrug strategy

Q and A Discussion

NETRF Scientific Advisors and Moderators
Panel Discussion: Key take-away points and priorities for future research

Meeting Adjourned